Small-Cap Stocks

3 Small-Cap Stocks Showing Strong Technical Performance

While large-cap stocks receive more attention from analysts and more investment, the author of today’s article reminds the reader that “small caps, over time, outperform their larger peers.” With that, she proceeds to highlight three small-cap stocks that are showing strong technical performance – including, in the biotech arena, a genetic-testing specialist. For more, CLICK HERE.

“Stockpicker’s Paradise”: 2 “Strong Buy” Penny Stocks With Upside Potential Over 200%

“We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain,” asserts one small/mid-cap stock strategist cited in today’s article, which proceeds to highlight two penny stocks that boast “Strong Buy” consensus ratings and upside potential over 200%. For these two penny stocks, CLICK HERE.

The Case For “Smidcaps”

Small and midcap stocks – or “smidcaps” – have had a strong November, and the author of today’s article asserts that this strong performance will continue: “This group has been beaten and battered for so long that many people simply doubt the move. But this is a big mistake. I don’t know about the next few days ahead, but smidcaps… 

Which Of These Small-Cap Biotechs With Unique COVID-19 Vaccine Candidates Is The Better Buy?

At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.

These 2 Small-Cap Biotech And Pharma Stocks Boast “Strong Buy” Ratings And Significant Upside Potential

Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.

Micro-Caps, Mega Gains?

Morgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per… 

Top Sectors & Stocks For A Return To Selective Stock Picking

Noting that we’re “beginning to see selectivity creep back into the marketplace following a period of indiscriminate buying”, the author of today’s article proceeds to identify the best sectors right now across large-cap, mid-cap and small-cap stocks, as well as a slew of “top scoring stocks” from those select sectors that may be the best buys for stock pickers right… 

A Portfolio For Aggressive Retirement Savers

Today’s article outlines a mutual fund portfolio for aggressive retirement savers – i.e. investors who are still many years away from retirement (or who are closer to retirement but already have their in-retirement income needs covered). As the author notes, these individuals can “reasonably hold more in potentially more volatile subasset classes, such as small-cap stocks and foreign stocks and… 

Can Small-Cap Stocks “Turbocharge” Your Retirement Savings Without Greater Risk?

For diligent retirement savers, the author of today’s article doesn’t see investing in large-cap stocks – with their maturity and predictable cash flows – as being a bad plan. However, for the large segment of Americans who are either behind on saving for retirement (or have no retirement savings at all), he points to small-cap stocks as being “the best…